Camstech Ltd in collaboration with Queen Mary University of Londonand the Barts Health NHS Trust is developing a novel technology for the rapid and sensitive detection of host resistance to therapeutic antibodies. With the increasing use of therapeutic monoclonal antibodies, resistance to these agents a major issue. The project outcome will be a rapid, simple and inexpensive point of care platform benefitting patients and saving costs to healthcare providers.
